Reinfection in American Cutaneous Leishmaniasis: Evaluation of Clinical Outcomes in the Hamster Model

Osorio, Yaneth; Gonzalez, S. J.; Gama, Vivian; Travi, Bruno L.

doi:10.1590/s0074-02761998000300015

Cited by 9 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11][12][13][14] It has long been postulated that infection of the host with one species of Leishmania might protect against re-infection with homologous or heterologous species. 22,23 However, in vitro studies of individual macrophage co-infections with different species of Leishmania suggest an absence of mutual exclusion if a second infection with a different strain occurs within a short window, 24 and recurrent infections in humans also imply some plasticity of this protective immune phenomenon. 25,26 The patient described in this report probably acquired the infection in the last leishmaniasisendemic region (Iberia), and although we cannot demonstrate definitively where this patient was infected, she was likely bitten by sand flies carrying different species over a short period in the same geographic location, thereby precluding development of any kind of partially protective immune response to infection by a second species.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous Infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian Patient with Cutaneous Leishmaniasis

Veland

Valencia²,

Alba³

et al. 2013

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Simultaneous Infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian Patient with Cutaneous Leishmaniasis

Veland

Valencia²,

Alba³

et al. 2013

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…OSORIO et al , (1998)11 pointed to the hamster model as an excellent tool for the study of leishmaniasis caused by parasites belonging to the subgenus Viannia due to it having shown susceptibility to these parasites and the similarity of the clinical symptoms to the ones presented in humans [in particular in relation to the presentation of chronic recurrent ulcers]. However in this study, no ulcerative lesions developed in juvenile hamsters by inoculation of 1 × 10 6 L. (V) panamensis promastigotes, while adult hamsters showed papules that contained parasites inside.…”

Section: Discussionmentioning

confidence: 99%

“…Hamsters are considered a suitable animal model for infection with Leishmania parasites of the subgenus Viannia (New World parasites) because of their special susceptibility to the infection with these species and because the chronic progression of the disease is similar to the one developed in humans that are naturally infected with Leishmania 3 11 12 13.…”

Section: Introductionmentioning

confidence: 99%

BODY WEIGHT AS A DETERMINANT OF CLINICAL EVOLUTION IN HAMSTERS (Mesocricetus auratus) INFECTED WITH Leishmania (Viannia) panamensis

Gomez-Galindo

Delgado

2013

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYThe clinical outcome of infection with Leishmania species of the subgenus Viannia in hamster model (Mesocricetus auratus) has shown to be different depending on experimental protocol. Body weight has been a relevant determinant of the clinical outcome of the infection in hamsters with visceral leishmaniasis but its importance as a clinical parameter in hamsters with cutaneous leishmaniasis is not known. In this study, the clinical evolution of infection with L. (V) panamensis was evaluated in juvenile and adult male hamsters during 11 weeks by comparing clinical parameters such as attitude, temperature, respiratory rate, appearance of the stool, and body weight between infected and non-infected groups. Results showed that body weight decreased in adult hamsters after infection by L. (V) panamensis; this observation supports the use of body weight as an additional parameter to define the management or treatment of cutaneous leishmaniasis in infected adult hamsters used as an animal experimental model for leishmaniasis.

show abstract

“…En el presente estudio, el empleo de un modelo animal, en conjunto con una cepa e inóculo definido de Leishmania eliminó algunos factores de confusión como: 1) la respuesta inmune variable del hospedero, 2) el tiempo posinfección, 3) el sitio de la lesión (4,16,17) y la heterogeneidad en la infectividad/patogenicidad de Leishmania (18).…”

Section: Discussionunclassified

Eficacia y toxicidad de los antimoniales pentavalentes (Glucantime y Pentostam) en un modelo animal de leishmaniasis cutánea americana: aplicación de la luminometría.

et al. 2004

View full text Add to dashboard Cite

Los antimoniales pentavalentes Glucantime® y Pentostam® son los medicamentos de primera línea usados en el tratamiento anti-Leishmania; sin embargo, no hay estudios in vivo que comparen su eficacia y toxicidad controlando variables del hospedero. Los estudios bioquímicos en Leishmania detectaron diferencias entre los dos medicamentos en la inhibición de la topoisomerasa I, que podrían reflejarse en diferencias en su efectividad. Para evaluar la eficacia clínica se infectaron hámsteres en la pata trasera derecha con 10 6 promastigotes de Leishmania panamensis silvestre y transfectada con el gen de la luciferasa. Para evaluar la eficacia parasitológica se estandarizó la cuantificación de parásitos en los tejidos por luminometría. Tres semanas después de la inoculación, los animales se trataron intramuscularmente con Glucantime® o Pentostam® (30, 60 o 120 mg de Sb V /kg por día por 20 días). La toxicidad se evaluó en hámsteres tratados intramuscularmente con 120, 160 o 240 mg de Sb V /kg por día por 20 días de Glucantime® o Pentostam®. La resolución de las lesiones en los animales inoculados con ambas cepas fue similar con ambos medicamentos. La carga parasitaria disminuyó de forma equivalente con ambos medicamentos en todas las dosis, y resultó en diferencias significativas con respecto a los controles (p<0,01). Los niveles séricos de creatinina, aspartato aminotransferasa, alanino aminotransferasa y amilasa no evidenciaron alteraciones hepáticas o renales. Los animales tratados con dosis iguales o mayores de 120 mg de Sb V /kg por día por 20 días de Pentostam® presentaron alteraciones inflamatorias micro y macroscópicas en el sitio de la inyección que no se observaron en los tratados con Glucantime®. Estos resultados confirman observaciones clínicas sobre la eficacia similar de ambos productos e indican una toxicidad local mayor del Pentostam®.Palabras clave: hámster, Leishmania panamensis, leishmaniasis/tratamiento, antimonio pentavalente, Glucantime®, Pentostam®, transfección, luminometría. Efficacy and toxicity of pentavalent antimonials (Glucantime® and Pentostam®) in an American cutaneous leishmaniasis animal model: luminometry applicationThe pentavalent antimonial compounds Glucantime® and Pentostam® are the first line drugs used in anti-Leishmania treatment. However, no in vivo studies have compared the efficacy and toxicity of these drugs where host variability has been controlled. Biochemical studies of Leishmania have detected differences between the two drugs with regard to DNA topoisomerase I inhibition, a phenomenon that possibly impacts treatment efficacy. To evaluate the clinical efficacy, hamsters were infected intradermally in the right hind foot with 10 6 promastigotes of a wild type or luciferase-transfected Leishmania panamensis. At three weeks post-inoculation, the animals were treated intramuscularly with either Glucantime® or Pentostam® (30, 60 or 120 mg Sb V /kg per day for 20 days). To evaluate parasitological efficacy a luminometry assay was standardized for quantitation of amastigotes i...

show abstract

Reinfection in American Cutaneous Leishmaniasis: Evaluation of Clinical Outcomes in the Hamster Model

Cited by 9 publications

References 15 publications

Simultaneous Infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian Patient with Cutaneous Leishmaniasis

Simultaneous Infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian Patient with Cutaneous Leishmaniasis

BODY WEIGHT AS A DETERMINANT OF CLINICAL EVOLUTION IN HAMSTERS (Mesocricetus auratus) INFECTED WITH Leishmania (Viannia) panamensis

Eficacia y toxicidad de los antimoniales pentavalentes (Glucantime y Pentostam) en un modelo animal de leishmaniasis cutánea americana: aplicación de la luminometría.

Contact Info

Product

Resources

About